|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.20 USD | -2.65% |
|
-1.42% | +14.51% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +64.87% | 12 | ||||||
| 819.18 | +21.06% | 26 | ||||||
| 287.95 | +20.33% | 19 | ||||||
| 2,052,158.8 | +47% | 24 | ||||||
| 96.64 | +12.23% | 16 | ||||||
| 226.29 | +9.86% | 30 | ||||||
| 48.26 | -21.93% | 19 | ||||||
| 113.82 | -2.93% | 22 | ||||||
| 101.47 | +32.1% | 25 | ||||||
| 494.67 | +7.12% | 12 | ||||||
| 104.78 | +28.75% | 21 | ||||||
| 280.39 | +21.91% | 20 | ||||||
| 87.96 | +47.61% | 25 | ||||||
| 361.67 | +1.92% | 9 | ||||||
| 458,000 | +65.64% | 5 | ||||||
| 14.36 | +58.21% | 12 | ||||||
| 88.5 | -5.7% | 10 | ||||||
| - | - | 61.5 | +39.54% | 1 | ||||
| 72.5 | +12.81% | 2 | ||||||
| - | - | 40.3 | +41.16% | 1 | ||||
| Average | 125,674.62 | +25.08% | 16 | ||||||
| Weighted average by Cap. | 228,197.2 | +20.53% | 20 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
